Technologies
PDF


WARF: P120376US02

Treating Multiple Sclerosis with UV Light


INVENTORS -

Hector DeLuca, Yanping Wang, Steven Marling

The Wisconsin Alumni Research Foundation (WARF) is helping develop a method to delay or alleviate the symptoms of multiple sclerosis by irradiating patients with a narrow band of ultraviolet light.
OVERVIEWMultiple sclerosis (MS) is a chronic autoimmune disease that afflicts more than 2.5 million people worldwide. Symptoms include weakness and numbing, pain, swallowing problems, blurred vision and difficulty moving. There is no cure for MS.

Several therapies, like anti-inflammatory steroids and immunosuppressive agents, have shown some promise for the treatment of MS symptoms. However, these treatments are associated with adverse side effects and are not effective for all patients.

While the exact cause of MS is unknown, sunlight and vitamin D production have long been thought to play a role. One piece of evidence is the fact that the disease is least prevalent at the equator and dramatically increases with latitude. Interestingly, new research suggests that light exposure – not subsequent vitamin D production – may be key to treating MS.
THE INVENTIONUW–Madison researchers have developed a method for suppressing MS symptoms by irradiating a patient with a narrow band of ultraviolet (UV) light. The light has a wavelength between about 300-315 nm. Patients could be irradiated using commercially available lamps or blankets. A typical treatment regimen could be 10-30 minutes of exposure for several days.
BUSINESS OPPORTUNITY
  • A cure for MS is a large and unmet medical need.
  • More than 350,000 individuals in the U.S. are affected.
  • 200 new cases are diagnosed each week.
  • Annual cost of MS in the U.S. is in the billions of dollars
APPLICATIONS
  • Treating or delaying the onset of multiple sclerosis symptoms
KEY BENEFITS
  • Method is simple and drug free.
  • Low cost
  • Could significantly improve the quality of life for patients with MS
  • The wavelength of light is in the generally safe UV-B range.
STAGE OF DEVELOPMENTThe researchers have extensive data showing the efficacy of UV-B wavelengths to stop the progression of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis.
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Wang Y., Marling S.J., McKnight S.M., Danielson A.L., Severson K.S. and Deluca H.F. 2013. Suppression of Experimental Autoimmune Encephalomyelitis by 300-315nm Ultraviolet Light. Arch Biochem Biophys. 536, 81-86.
Contact Information
For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.